Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial

• Published in: Acta anaesthesiologica Scandinavica 2008-01, Vol.52 (1), p.65-72
• Main Authors: REX, S., SCHAELTE, G., METZELDER, S., FLIER, S., DE WAAL, E. E. C., AUTSCHBACH, R., ROSSAINT, R., BUHRE, W.
• Format: Article
• Language: English
• Subjects: Administration, Inhalation; Aged; Anesthesia; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Cardiac Output, Low - drug therapy; Cardiac Output, Low - etiology; Cardiopulmonary Bypass; Catheterization, Swan-Ganz; Echocardiography, Transesophageal; Female; Humans; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - etiology; Iloprost - administration & dosage; Iloprost - pharmacology; Iloprost - therapeutic use; Infusions, Intravenous; inhaled iloprost; Male; Medical sciences; Middle Aged; Milrinone - therapeutic use; Mitral Valve Insufficiency - complications; Mitral Valve Insufficiency - physiopathology; Mitral Valve Insufficiency - surgery; mitral valve surgery; Monitoring, Intraoperative; Nitroglycerin - administration & dosage; Nitroglycerin - therapeutic use; Postoperative Complications - drug therapy; Postoperative Complications - etiology; Prospective Studies; pulmonary hypertension; pulmonary vascular resistance; right ventricular ejection fraction; Right ventricular failure; Stroke Volume - drug effects; Vascular Resistance - drug effects; Vasodilator Agents - administration & dosage; Vasodilator Agents - pharmacology; Vasodilator Agents - therapeutic use; Ventricular Dysfunction, Right - diagnostic imaging; Ventricular Dysfunction, Right - etiology; Ventricular Dysfunction, Right - prevention & control
• ISSN: 0001-5172; 1399-6576
• DOI: 10.1111/j.1399-6576.2007.01476.x

Background: Pulmonary hypertension (PHT) is common in patients undergoing mitral valve surgery and is an independent risk factor for the development of acute right ventricular (RV) failure. Inhaled iloprost was shown to improve RV function and decrease RV afterload in patients with primary PHT. However, no randomized‐controlled trials on the intraoperative use of iloprost in cardiac surgical patients are available. We therefore compared the effects of inhaled iloprost vs. intravenous standard therapy in cardiac surgical patients with chronic PHT. Methods: Twenty patients with chronic PHT undergoing mitral valve repair were randomized to receive inhaled iloprost (25 μg) or intravenous nitroglycerine. Iloprost was administered during weaning from cardiopulmonary bypass (CPB). Systemic and pulmonary haemodynamics were assessed with pulmonary artery catheterization and transoesophageal echocardiography. Milrinone and/or inhaled nitric oxide were available as rescue medication in case of failure to wean from CPB. Results: Inhaled iloprost selectively decreased the pulmonary vascular resistance index after weaning from CPB (208 ± 108 vs. 422 ± 62 dyn·s/cm5/m2, P